Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Aug 31;112(35-36):601.
doi: 10.3238/arztebl.2015.0601a.

Marginal Effect and Little Clinical Relevance

B Mühlbauer, G W Sybrecht
Comment

Marginal Effect and Little Clinical Relevance

B Mühlbauer et al. Dtsch Arztebl Int. .
No abstract available

PubMed Disclaimer

Comment in

  • In Reply.
    Lommatzsch M, Virchow JC. Lommatzsch M, et al. Dtsch Arztebl Int. 2015 Aug 31;112(35-36):601-2. doi: 10.3238/arztebl.2015.0601c. Dtsch Arztebl Int. 2015. PMID: 26377534 Free PMC article. No abstract available.

Comment on

References

    1. Lommatzsch M, Virchow JC. Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int. 2014;111:847–855. - PMC - PubMed
    1. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–582. - PubMed
    1. Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012;49:144–152. - PubMed
    1. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316. - PubMed

MeSH terms

Substances